Primopus Revenue and Competitors

Primopus AG\n(formerly Escientia Switzerland AG)\n \nPrimopus is a CMO/CDMO and producer of complex RSM’s, GMP intermediates and API’s. We operate out of a former Novartis API plant near Basel, Switzerland. It is equipped with over 250m3 reactor capacity in a 17,000m2 plant with ample capacity to make key API ingredients. The plant has made innovator intermediates and API’s for over 30 years with an outstanding track record.\n \nOur value proposition is to offer fully integrated small molecule supply from our Swiss site with backward integration through 3 large sites of our parent company, Deccan Fine Chemicals, in India. Responding to the post-Covid trend to de-risk and diversify supply chain, we offer a hybrid model and the best of several worlds at a competitive price.\n\nWe rely on a large PR&D and scale-up team at our Goa, India site and are establishing an R&D capability at our Swiss site.\n\nThe plant is being upgraded and modernized including full DCS automation and a digital GMP compliant document management system.\n\nSustainability is at the core of how we do things. Our Swiss site will be net zero carbon by 2028 for all utilities and thereafter we will meet the COP26 goals of net zero carbon by 2050.